Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:pertuzumab
|
| gptkbp:aims_to |
treatment efficacy
safety profile |
| gptkbp:analyzes |
neoadjuvant therapy
|
| gptkbp:associated_with |
HE R2-targeted therapy
|
| gptkbp:clinical_trial |
NC T01042379
neoadjuvant trials other HE R2 studies |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:collection |
clinical assessments
patient-reported outcomes biomarker analysis |
| gptkbp:completed |
gptkb:2013
|
| gptkbp:conducted |
clinical researchers
|
| gptkbp:criteria |
pregnancy
previous cancer treatment stage II or III breast cancer HE R2-positive status |
| gptkbp:events |
ongoing research
quality of life assessments long-term outcomes analysis |
| gptkbp:finale_date |
efficacy of treatment
safety of treatment |
| gptkbp:focuses_on |
HE R2-positive breast cancer
|
| https://www.w3.org/2000/01/rdf-schema#label |
NEOSPHERE trial
|
| gptkbp:involves |
gptkb:pertuzumab
gptkb:trastuzumab chemotherapy |
| gptkbp:is_studied_in |
randomized controlled trial
|
| gptkbp:is_tested_for |
Phase II
|
| gptkbp:launched |
gptkb:2010
|
| gptkbp:location |
multiple sites
|
| gptkbp:notable_work |
improved p CR rates
potential for new treatment protocols tolerable side effects |
| gptkbp:outcome |
clinical practice
|
| gptkbp:participants |
overall survival
patients with breast cancer disease-free survival pathological complete response |
| gptkbp:provides_information_on |
breast cancer treatment guidelines
HE R2 therapy recommendations |
| gptkbp:receives_funding_from |
government grants
private funding |
| gptkbp:recruitment |
completed
|
| gptkbp:research_areas |
oncology
breast cancer research clinical oncology |
| gptkbp:result |
gptkb:2015
medical journals |
| gptkbp:sponsor |
pharmaceutical companies
|